![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Ipca Laboratories Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Telmisartan, supported by a 'Valid' Certificate of Suitability (CEP) with the number CEP 2020-211 - Rev 02
This Chemical Type CEP, issued on December 20, 2023, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2154 associated with this CEP further emphasizes